Aduhelm Shows Need For More FDA Transparency On Approval Decisions, Surrogate Endpoints, Critics Say

 
• By Sue Sutter
Thorns
Twenty months later, the Aduhelm accelerated approval remains a thorn in CDER's side. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards